Abstract:Abstract Next-generation sequencing (NGS) of urologic tumor genomes has identified frequently altered cancer genes. We recently examined the exomes of bladder tumors (BCa) from 54 U.S. patients and 99 Chinese patients to identify novel, altered cancer genes associated with clinical characteristics of disease. Exome capture of DNA from tumor and normal urothelial tissue using probes for ~180,000 protein-coding exons and microRNA loci; DNA fragment libraries were sequenced on a HiSeq 2000 platform (Illumina); and base calls on paired-end, 100 bp reads were generated using the Genome Analyzer Pipeline, v. 1.3 and standard parameters. Gene expression was analyzed using quantitative PCR, telomere length by a standard assay, and KDM6A function using cell-based assays in T24T BCa cells. Copy number variation (CNV), aneuploidy, and CpG methylation were analyzed as recently described. Telomerase (TERT) was the most frequently altered by somatic sequence changes in 37/54 (69%) of U.S. patient tumors. The TERT promoter was altered by frequent germline nucleotide changes in 30/54 (56%) tumors. Most of the TERT germline variants were novel (19/20) and three variants were confirmed in distinct tumors as either somatic or germline, including the most frequent variant, c. –245 T>C (rs2853669). The somatic TERT promoter alterations did not correlate with other somatic BCa gene alterations, but were associated with increased TERT expression and with significantly shorter telomeres in tumors as compared to matched normal tissue. The stromal antigen 2 (STAG2) gene was the most frequently altered novel BCa gene in Chinese patients, by somatic, deleterious sequence changes in 11% of tumors; CNV deletions (5%); and promoter CpG hypermethylation leading to presumed expression silencing (7/30, 23%). STAG2 encodes a component of the cohesion complex involved in sister chromatid cohesion and segregation. STAG2 mutations were associated with an increased number of chromosomal arm copy number changes corresponding to higher tumor cell aneuploidy, and mutations were associated with a significantly reduced patient survival by Kaplan-Meier survival analysis. In total, 32/99 (32%) of tumors displayed SCCS pathway gene alterations. The most frequently altered epigenetic gene was the histone lysine-specific demethylase 6A (KDM6A/UTX) in 24% of U.S. and 30% of Chinese patient tumors. Experimentally, we show KDM6A loss in human BCa T24T cells enhanced in vitro proliferation and cell migration, and in vivo tumor growth in mice. Re-expression reversed these effects, confirming KDM6A loss drives the BCa phenotype. Somatic KDM6A alterations were associated with somatic BRCA1-associated protein-1 (BAP1) alterations observed in 15% of U.S. tumors. Somatic, deleterious sequence changes occurred preferentially in U.S. Caucasian as compared to Chinese BCa patient tumors; are associated with papillary histologic features in a subset of tumors; and contribute to a significant number of tumors (10/14, 71%) that displayed alteration of genes encoding BRCA DNA repair pathway proteins. Genes encoding BRCA pathway proteins, including BAP1, BRCA1, BRCA2, PALB2, and ATM were altered by a combination of somatic and rare germline variants. We identified altered genes associated with clinical characteristics of BCa, including ‘immortalization' (TERT), aneuploidy (STAG2), proliferation (KDM6A), and papillary features in tumors (BAP1). STAG2 alterations are associated with a reduced patient survival, indicating a lethal subtype of disease; and altered X chromosome genes (STAG2 and KDM6A) are single copy in males and likely contribute to the cancer gender bias. Finally, we identified BRCA pathway alterations in BCa that are similar to those in breast, ovarian, prostate and kidney tumors, that have a common DNA repair deficiency that can be exploited by therapy targeting poly (ADP ribose) polymerase. Citation Format: Mike Nickerson, Kate M. Im, Guangwu Guo, Yaoting Gui, Sevilay Turan, James C. Costello, Quan Zhou, Zhiming Cai, Song Wu, M. Scott Lucia, Lee E. Moore, Michael Dean, Dan Theodorescu. Gene alterations associated with clinical characteristics of bladder cancer. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr A52.

MP45-14 EPIGENETIC REGULATION OF CANDIDATE TUMOR SUPPRESSOR GENE ADAMTS18 IN HUMAN BLADDER CANCER ASSOCIATED WITH ITS PROGNOSIS

Overexpression of the ASPM Gene is Associated with Aggressiveness and Poor Outcome in Bladder Cancer.

MP27-03 HYPERMETHYLATION OF THE RASSF1A GENE PROMOTER AT CYTOSINE GUANINE DINUCLEOTIDE ISLANDS PREDICTS HIGHER MALIGNANT POTENTIAL BUT BETTER URINARY TRACT RECURRENCE-FREE SURVIVAL IN UPPER TRACT UROTHELIAL CARCINOMA PATIENTS AFTER SURGERY

MP2-03 PROGNOSTIC AND PREDICTIVE VALUE OF EPIGENETIC BIOMARKERS IN UPPER TRACT UROTHELIAL CARCINOMA

Hypermethylation Of The 16q23.1 Tumor Suppressor Gene Adamts18 In Clear Cell Renal Cell Carcinoma

Long Noncoding RNA ADAMTS9-AS2 Inhibits the Proliferation, Migration, and Invasion in Bladder Tumor Cells

The expression of ADAMTS14 is regulated by promoter DNA methylation and is associated with poor prognosis in colorectal cancer

MicroRNA-186 suppresses cell proliferation and metastasis in bladder cancer

N1-methyladenosine methylation in mRNAs drives bladder cancer progression

THE B4GALT1 EXPRESSION IS PROGNOSTIC AND PREDICTIVE FOR POSTOPERATIVE ADJUVANT CHEMOTHERAPY BENEFIT IN PATIENTS WITH MUSCLE‐INVASIVE BLADDER CANCER: MP58‐08

MP55-10 EPIGENETIC REGULATION OF THE 3P22 TUMOR SUPPRESSOR DLEC1 IN HUMAN PROSTATE CANCER ASSOCIATED WITH ITS PROGNOSIS

Abstract A52: Gene Alterations Associated with Clinical Characteristics of Bladder Cancer

MP58-08 CANCER-ASSOCIATED FIBROBLASTS SECRETED EXOSOMAL MIR-146A PROMOTES BLADDER CANCER CHEMORESISTANCE

The role of Lutheran/basal cell adhesion molecule in human bladder carcinogenesis

MP39-12 CARBONIC ANHYDRASE X, A NOVEL PUTATIVE TUMOR SUPPRESSOR SILENCED BY PROMOTER CPG METHYLATION, SUPPRESSES GROWTH AND INVASIVENESS OF RENAL CELL CARCINOMA

ADAMTS8 Inhibits Cell Proliferation and Invasion, and Induces Apoptosis in Breast Cancer

MP48-05 IDENTIFICATION OF CCDC34 AS AN ONCOGENE IN BLADDER CANCER AND ITS FUNCTION DURING BLADDER CARCINOGENESIS

MP44-02 IDENTIFICATION AND VALIDATION OF C1ORF198 AS AN INDEPENDENT MARKER OF BLADDER CANCER METASTASIS IN SEER AND TCGA DATABASE

MP36-01 MITOCHONDRIAL DNA CONTENT AS RISK FACTOR FOR BLADDER CANCER AND ITS ASSOCIATION WITH MITOCHONDRIAL DNA POLYMORPHISMS

Integrated Analysis Reveals Molecular Features of Upper Tract Urothelial Carcinoma and Prognostic Value of Neutrophil Infiltration for Adjuvant Chemotherapy

Mp85-14 aberrant methylation of ccnd2 is associated with loss of expression and tumor pathylogical subtypes in renal cell cancer